imyn/drug reverse ms/Inflammation is at the core of many common diseases. Initial proof of concept studies on humans and animals, already undertaken by Argyll Biotechnologies; strongly suggest that its SF-1019 platform technology, with its ability to induce both an adaptive and innate human immune response, combined with its extensive anti-inflammatory and analgesic properties, amongst others, may be of benefit in the treatment of many human diseases.
SF-1019 was initially developed as an aid to wound healing and to treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). However, it is believed that SF-1019 might be of additional benefit, either in its existing form or with disease specific peptide adjustments or adaptations for treatment of some Cancers and Inflammatory Bowel Diseases. Such diseases and conditions might include Ulcerative Colitis and Crohn's Disease, Atherosclerosis which can lead to heart attack or stroke, Osteoarthritis, Chronic Obstructive Pulmonary (Lung) Disease, Rheumatoid Arthritis, Multiple Sclerosis, Diabetes and many neurodegenerative diseases such as Alzheimer's, Lou Gehrig's Disease, HIV / AIDS Psoriasis, and others with an inflammatory component attached to them.
The need to understand and develop treatments for inflammatory and infectious diseases is critical, as it is currently estimated that within the next ten years many of the antibiotics currently employed for treating bacterial infections will no longer be effective due to microbial resistance.
As part of its first stage strategy, Argyll Biotechnologies and its research partners are currently preparing a comprehensive program designed to examine the potential of SF-1019 and develop effective treatments for:
•Various cancers •Asthma and Chronic Obstructive Pulmonary Disease (COPD) •Inflammation of the heart (Myocarditis) •Lou Gehrig's Disease (motor neurone) •Type 2 Diabetes up 4 fda
great article Recent SF-1019 Study In no case was there a negative showing as to a safety issue and in most there was a measurable improvement in a clinical condition SF-1019 has shown great promise over a wide range of applications relating to conditions of an inflammatory nature such as Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS).
Following a series of toxicity studies in animals, SF-1019 demonstrated a positive safety profile.
Recently, in one of Argyll Biotechnologies’ pre-clinical human studies, a small number of patients were provided with SF-1019 treatments under informed consent (EU) and a compassionate waiver program (US). Information collected from this study extended over a ten month period and included a brief record of clinical progress (if any), together with dose ranging and toxicity data.
A standard battery of blood tests were undertaken pre-treatment and at four, eight and twelve week intervals. In no case was there a negative showing as to a safety issue and in most there was a measurable improvement in a clinical condition. For example, there were no apparent biochemical changes in the blood analysis and no adverse reactions recorded in this group.
Many of the patients who participated in this program continue to receive compassionate treatments of SF-1019.